Cancer Genetics (NASDAQ:CGIX) Research Coverage Started at

Equities research analysts at started coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Price Performance

Cancer Genetics stock opened at $0.83 on Tuesday. The business’s fifty day simple moving average is $1.10 and its two-hundred day simple moving average is $0.87. Cancer Genetics has a 12 month low of $2.11 and a 12 month high of $17.50.

Cancer Genetics Company Profile

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Featured Articles

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.